Copyright © 2021. Inderes Oyj. All rights reserved.
Käyttäjätili

Hei anonyymi!

Luomalla maksuttoman Inderes-tilin, pääset käsiksi Inderesin analyysiin, voit tilata suositun aamukatsauksen ja seurata sinua kiinnostavia yhtiöitä sekä keskusteluita.

Luo tili

Onko sinulla jo Inderes-tili?

Ascelia Pharma

Viimeisimmät raportit

Laaja raportti

Analyytikko

Henrik Ekman

Henrik Ekman

Research

Lisätiedot

Sisäpiirin kaupat

Nettovaikuttavuus

Muut analyysit
4.11.
2022

Ascelia is reporting progress towards pivotal results with contained operational costs and cashflow.

Tiedotteet
4.11.
2022

Ascelia Pharma AB (publ) (ticker: ACE) today published its quarterly financial report for Q3 2022(January – September 2022), which is now available on the company’s website:

Tiedotteet
5.10.
2022

Ascelia Pharma AB (publ) (ticker: ACE) a biotech focused on improving the life of people living with rare cancer conditions, today announced that it has expanded its leadership team to include all line functions that report directly to CEO Magnus Corfitzen. The company’s Chief Medical Officer (CMO) Carl Bjartmar has decided to retire by the end of 2022.

Ascelia Pharma’s new leadership team will consist of the following seven members:

Tiedotteet
28.9.
2022

Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced the final results of the Hepatic Impairment Study confirming that the company’s lead drug candidate, the magnetic resonance imaging (MRI) contrast agent Orviglance®, is well tolerated in patients with hepatic impairment.

Muut analyysit
18.8.
2022

Ascelia’s pivotal study seems to be on track, and the company repeats the goal to reach the full enrolment of 50 patients in 2022.

Tiedotteet
18.8.
2022

Ascelia Pharma AB (publ) (ticker: ACE) today published its half-year financial report for 2022 (January – June 2022), which is now available on the company’s website: https://www.ascelia.com/ir-media/financial-reports/

SIGNIFICANT EVENTS IN Q2 2022

Tiedotteet
11.8.
2022

Ascelia Pharma AB (publ) (ticker: ACE) today announced that results from the Orviglance® Food Effect Study have been accepted as an oral presentation at the world’s largest radiology conference, RSNA. The conference will be held November 27 – December 1 in Chicago, Illinois.

Tiedotteet
20.6.
2022

Ascelia Pharma AB (publ) (ticker: ACE) today announced that it has appointed Déspina Georgiadou Hedin as Chief Financial Officer (CFO). She has a strong background in finance, most recently as CFO and HR Manager at Bioglan. She will take up her new position at Ascelia Pharma in September and report to CEO Magnus Corfitzen.

Tiedotteet
1.6.
2022

Ascelia Pharma AB (publ) (ticker: ACE) today presented results at the annual ESGAR conference in Lisbon, Portugal, from the study in which the investigational contrast agent Orviglance® was compared to a gadolinium-based contrast agent.

Tiedotteet
31.5.
2022

Ascelia Pharma AB (publ) (ticker: ACE) today announced that the US Patent and Trademark Office (USPTO) has issued a notice of allowance for a second Oncoral patent application covering the method of use of Oncoral.

Ascelia Pharma

ipo